Earnings summaries and quarterly performance for OptimizeRx.
Executive leadership at OptimizeRx.
Steve Silvestro
Detailed
Chief Executive Officer
CEO
AD
Andy D’Silva
Detailed
Chief Business Officer
BM
Brendan Merrell
Detailed
Chief Operating Officer
DB
Doug Besch
Detailed
Chief Product & Technology Officer
ES
Edward Stelmakh
Detailed
Chief Financial & Strategic Officer
MO
Marion Odence-Ford
Detailed
Chief Legal & Administrative Officer
TG
Theresa Greco
Detailed
Chief Commercial Officer
Board of directors at OptimizeRx.
Research analysts who have asked questions during OptimizeRx earnings calls.
David Grossman
Stifel
6 questions for OPRX
Also covers: DCGO, DH, DRIO +3 more
CD
Constantine Davides
Citizens JMP
5 questions for OPRX
Also covers: ADUS, AMN, CCRN +9 more
Eric Martinuzzi
Lake Street Capital Markets
4 questions for OPRX
Also covers: APEI, ASPU, ASUR +24 more
RD
Ryan Daniels
William Blair & Company, L.L.C.
4 questions for OPRX
Also covers: ACCD, AGL, ALHC +12 more
Jeffrey Garro
Stephens Inc.
3 questions for OPRX
Also covers: ACCD, CERT, DH +9 more
RB
Richard Baldry
ROTH MKM
3 questions for OPRX
Also covers: AEYE, ASUR, CYRX +9 more
AS
Anderson Schock
B. Riley Securities
2 questions for OPRX
Also covers: ANIK, CLPT, ELMD +8 more
JG
Jeff Garro
Stephens
2 questions for OPRX
Also covers: CERT, DH, DOCS +6 more
JH
Jared Haase
William Blair & Company
1 question for OPRX
Also covers: ADUS, ALHC, BTSG +11 more
KB
Kyle Bauser
B. Riley Securities
1 question for OPRX
Also covers: ELMD, INFU, IRMD +7 more
MM
Maxwell Michaelis
Lake Street Capital Markets
1 question for OPRX
Also covers: APEI, BCOV, BLZE +11 more
Sean Dodge
RBC Capital Markets
1 question for OPRX
Also covers: BTSG, CDMO, CTLT +15 more
SD
Stephanie Davis
Barclays
1 question for OPRX
Also covers: ACCD, CAH, COR +20 more
Recent press releases and 8-K filings for OPRX.
OptimizeRx Reports Q4 and Full-Year 2025 Results, Updates 2026 Guidance
OPRX
Earnings
Guidance Update
Share Buyback
- OptimizeRx reported Q4 2025 revenue of $32.2 million and adjusted EBITDA of $12 million, contributing to full-year 2025 revenue of $109.4 million and adjusted EBITDA of $24.3 million.
- The company provided 2026 guidance with expected revenue between $109 million and $114 million and adjusted EBITDA between $21 million and $25 million.
- A $10 million share repurchase program was authorized, with the company ending 2025 with $23.4 million in cash and short-term investments.
- Management observed softness in year-to-date contracted revenue for 2026, primarily due to a market shift from managed services (which contributed $9 million in H1 2025) and client caution regarding Most-Favored-Nation pricing.
- OptimizeRx is actively converting DAAP agreements to a subscription model, achieving nearly 10% of revenue on a subscription run rate by the end of 2025, and views AI as a tailwind rather than a disruption.
19 hours ago
OptimizeRx Reports Strong Q4 and FY 2025 Results, Updates 2026 Guidance, and Authorizes Share Repurchase
OPRX
Earnings
Guidance Update
Share Buyback
- OptimizeRx reported Q4 2025 revenue of $32.2 million and adjusted EBITDA of $12 million, contributing to full-year 2025 revenue of $109.4 million and adjusted EBITDA of $24.3 million.
- For 2026, the company updated its guidance, projecting revenue between $109 million and $114 million and adjusted EBITDA between $21 million and $25 million.
- This revised guidance reflects softness in contracted revenue due to a market shift away from managed services and clients adopting a more conservative spending tone related to Most-Favored-Nation pricing.
- The board authorized a $10 million share repurchase program, and the company is focused on increasing utilization of its DAAP platform and transitioning more customers to a subscription-based model, with the DAAP subscription mix exiting 2025 close to a 10% run rate.
19 hours ago
OptimizeRx Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance, and Authorizes Share Repurchase
OPRX
Earnings
Guidance Update
Share Buyback
- OptimizeRx delivered Q4 2025 revenue of $32.2 million and adjusted EBITDA of $12 million, contributing to full-year 2025 revenue of $109.4 million and adjusted EBITDA of $24.3 million.
- The company announced 2026 guidance, expecting revenue in the range of $109 million to $114 million and adjusted EBITDA between $21 million and $25 million.
- The board authorized a $10 million share repurchase program, which will be financed using available cash and cash equivalents.
- Gross margin for Q4 2025 increased to 74.8% from 68.1% in Q4 2024, driven by a favorable solution and channel partner mix, though 2026 gross margins are anticipated to be in the mid-60% range.
- Management noted softness in year-to-date contracted revenue for 2026, primarily due to a market shift away from managed services, which contributed $9 million in the first half of 2025, and a more conservative spending tone from clients adjusting to Most-Favored-Nation pricing.
20 hours ago
OptimizeRx Reports Strong Q4 and Full Year 2025 Financial Results
OPRX
Earnings
Guidance Update
Share Buyback
- OptimizeRx reported Q4 2025 revenue of $32.2 million and full year 2025 revenue of $109.4 million, representing a 19% increase year-over-year.
- The company achieved record Q4 net income of $5.0 million and adjusted EBITDA of $12.0 million. Full year 2025 adjusted EBITDA was $24.3 million.
- OptimizeRx updated its 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million.
- The Board authorized a $10 million share repurchase program, effective March 12, 2026.
20 hours ago
OptimizeRx Reports Strong Q4 and Full Year 2025 Results, Updates 2026 Guidance, and Authorizes Share Repurchase
OPRX
Earnings
Guidance Update
Share Buyback
- OptimizeRx reported Q4 2025 revenue of $32.2 million and full-year 2025 revenue of $109.4 million, representing a 19% increase year-over-year.
- Adjusted EBITDA for Q4 2025 increased to $12.0 million, with full-year 2025 Adjusted EBITDA reaching $24.3 million.
- The company updated its 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million.
- OptimizeRx's Board authorized a $10 million share repurchase program, effective March 12, 2026.
21 hours ago
OptimizeRx Reports Strong Q4 and Full Year 2025 Financial Results, Updates 2026 Guidance, and Authorizes Share Repurchase Program
OPRX
Earnings
Guidance Update
Share Buyback
- OptimizeRx reported Q4 2025 revenue of $32.2 million and full-year 2025 revenue of $109.4 million, representing a 19% increase year-over-year for the full year. The company achieved record Q4 2025 net income of $5.0 million ($0.26 per diluted share) and Adjusted EBITDA of $12.0 million.
- For the full year 2025, GAAP net income was $5.1 million ($0.27 per diluted share) and Adjusted EBITDA totaled $24.3 million.
- The company updated its 2026 guidance, projecting revenue to be between $109 million and $114 million and Adjusted EBITDA between $21 million and $25 million.
- OptimizeRx's Board of Directors authorized a $10 million share repurchase program, effective March 12, 2026, and set to expire by March 15, 2027. The company also extended its financing agreement's maturity date by two years to October 11, 2029, and paid off an incremental $2 million in principal from its term loan during Q4 2025. Cash and cash equivalents stood at $23.4 million as of December 31, 2025.
21 hours ago
OptimizeRx Expands Point-of-Care Network with New Partner Agreements
OPRX
New Projects/Investments
Revenue Acceleration/Inflection
- OptimizeRx Corp. announced four new partner agreements on December 17, 2025, significantly expanding its in-workflow point-of-care (POC) network and increasing its total National Provider Identifier (NPI) reach.
- Key agreements include an exclusive, multi-year partnership with a high-demand e-prescribing (eRx) platform previously unavailable to OptimizeRx, and a new partnership extending its presence into the point-of-discharge setting.
- The company also secured multi-year renewals with two high-performing EHR and eRx partners, one of which establishes an exclusive partnership.
- These new channel partners are projected to increase OptimizeRx's unique NPI reach by 37%.
- CEO Steve Silvestro stated these strategic moves are expected to position the company for sustained, profitable growth and enhance client value.
Dec 17, 2025, 9:30 AM
OPRX Discusses Q3 2025 Performance and Provides 2026 Outlook
OPRX
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- OptimizeRx is transitioning to a more predictive and smoother revenue model, driven by the growth of subscription-like DAAP and Micro-Neighborhood audience products, which has led to increased visibility into 2026.
- For Q4 2025, the company expects implied revenue to be slightly down year-over-year at the top end of guidance, while Adjusted EBITDA could be slightly down to narrowly up sequentially, primarily due to conservative gross margin assumptions and stable operating expenses.
- Gross margins in Q3 2025 expanded due to a favorable product mix and better channel partner deals, with future margins anticipated to stabilize in the upper 50s to low 60s range.
- The company is piloting a "very large" partnership with Lamar Advertising to integrate its patient-finding capabilities with digital screens, although no contributions from this partnership are currently factored into the 2026 guidance.
Nov 6, 2025, 9:30 PM
OPRX Discusses Q3 2025 Performance, Business Model Evolution, and 2026 Outlook
OPRX
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- OPRX is migrating towards a more predictive and smoother revenue model, driven by outsized growth in DAP and micro neighborhood audience, which are more subscriptive in nature, providing greater visibility into 2026.
- While implied Q4 2025 revenue guidance may appear slightly down year-over-year, management emphasizes looking at full-year performance and states the guidance reflects true, conservative visibility, aiming to beat numbers.
- RFP season has been strong, with increased interest in both HCP and DTC segments, and an improving win rate due to better client engagement.
- Gross margin expansion in Q3 2025 was attributed to product and channel mix, growth in DAP and GTC platforms, and less managed services revenue (a lower-margin product). Future gross margins are expected to stabilize in the upper 50s to low 60s range.
- The company maintains a highly leverageable business model, expecting a relatively stable operating expense run rate on a cash basis, despite an increase in cash operating expenses due to bonuses tied to top-line overperformance. The 2026 guidance does not factor in contributions from the new Lamar Advertising partnership.
Nov 6, 2025, 9:30 PM
OptimizeRx Discusses Q3 2025 Performance and Future Outlook
OPRX
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- OptimizeRx's implied Q4 2025 revenue guidance suggests a slight year-over-year decrease at the top end, with adjusted EBITDA expected to be flat to slightly up, though management emphasizes a full-year perspective due to smoother revenue phasing.
- The company is gaining increased visibility into 2026 due to a migration towards a more predictive, subscription-like revenue model, particularly from DAP and Micro-neighborhood audience growth, allowing for a general guide for the year based on renewals and signed contracts.
- Gross margins are expected to stabilize in the upper 50s to low 60s range for Q4 2025 and going forward, driven by product mix, channel partner negotiations, and growth in DAP and DTC platforms.
- The RFP season has been strong, with increased client interest in digital solutions for both HCP and DTC, and the company is experiencing improved win rates.
Nov 6, 2025, 9:30 PM
Quarterly earnings call transcripts for OptimizeRx.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more